APO Research
Talk to an analyst

APO RESEARCH · REPORT

RNA-Targeted Small Molecule Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global RNA-Targeted Small Molecule Drugs Market Analysis and Forecast 2026-2032

4 January 2026192 pages

Choose your research edition.

Industry ResearchRNA-Targeted Small Molecule Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal RNA-Targeted Small Molecule Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal RNA-Targeted Small Molecule Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNA-Targeted Small Molecule Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal RNA-Targeted Small Molecule Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global RNA-Targeted Small Molecule Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for RNA-Targeted Small Molecule Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for RNA-Targeted Small Molecule Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for RNA-Targeted Small Molecule Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for RNA-Targeted Small Molecule Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of RNA-Targeted Small Molecule Drugs include Roche, Novartis, PTC Therapeutics, Biogen, Accent Therapeutics, Anima Biotech, Arrakis Pharmaceuticals, Epics Therapeutics and Expansion Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for RNA-Targeted Small Molecule Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of RNA-Targeted Small Molecule Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for RNA-Targeted Small Molecule Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the RNA-Targeted Small Molecule Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global RNA-Targeted Small Molecule Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for RNA-Targeted Small Molecule Drugs revenue, projected growth trends, production technology, application and end-user industry.

RNA-Targeted Small Molecule Drugs Segment by Company

Roche

Novartis

PTC Therapeutics

Biogen

Accent Therapeutics

Anima Biotech

Arrakis Pharmaceuticals

Epics Therapeutics

Expansion Therapeutics

Gotham Therapeutics

H3 Biomedicine

Ribometrix

Skyhawk Therapeutics

STORM Therapeutics

Twentyeight-Seven Therapeutics

RNA-Targeted Small Molecule Drugs Segment by Type

mRNA Translation Regulation

RNA Splicing Modification

Direct RNA Targeting

Indirect RNA Targeting - Epitranscriptomics

RNA-Targeted Small Molecule Drugs Segment by Application

SMA

Oncology

Lung Fibrosis

Huntington's Disease

Others

RNA-Targeted Small Molecule Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA-Targeted Small Molecule Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNA-Targeted Small Molecule Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA-Targeted Small Molecule Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of RNA-Targeted Small Molecule Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of RNA-Targeted Small Molecule Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, RNA-Targeted Small Molecule Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. mRNA Translation Regulation Major Player Table 3. RNA Splicing Modification Major Player Table 4. Direct RNA Targeting Major Player Table 5. Indirect RNA Targeting - Epitranscriptomics Major Player Table 6. Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. SMA Major Player Table 8. Oncology Major Player Table 9. Lung Fibrosis Major Player Table 10. Huntington's Disease Major Player Table 11. Others Major Player Table 12. RNA-Targeted Small Molecule Drugs Industry Trends Table 13. RNA-Targeted Small Molecule Drugs Industry Drivers Table 14. RNA-Targeted Small Molecule Drugs Industry Opportunities and Challenges Table 15. RNA-Targeted Small Molecule Drugs Industry Restraints Table 16. Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global RNA-Targeted Small Molecule Drugs Market Size by Region (2021-2026) & (US$ Million) Table 18. Global RNA-Targeted Small Molecule Drugs Market Share by Region (2021-2026) Table 19. Global RNA-Targeted Small Molecule Drugs Market Size by Region (2027-2032) & (US$ Million) Table 20. Global RNA-Targeted Small Molecule Drugs Market Share by Region (2027-2032) Table 21. Global RNA-Targeted Small Molecule Drugs Revenue by Players (US$ Million) & (2021-2026) Table 22. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Players (2021-2026) Table 23. Global RNA-Targeted Small Molecule Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global RNA-Targeted Small Molecule Drugs Key Players Headquarters & Area Served Table 25. Global RNA-Targeted Small Molecule Drugs Players, Product Type & Application Table 26. Global RNA-Targeted Small Molecule Drugs Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global RNA-Targeted Small Molecule Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global RNA-Targeted Small Molecule Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2026) & (US$ Million) Table 31. Global RNA-Targeted Small Molecule Drugs Revenue by Type (2027-2032) & (US$ Million) Table 32. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Type (2021-2026) Table 33. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Type (2027-2032) Table 34. Global RNA-Targeted Small Molecule Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2026) & (US$ Million) Table 36. Global RNA-Targeted Small Molecule Drugs Revenue by Application (2027-2032) & (US$ Million) Table 37. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Application (2021-2026) Table 38. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Application (2027-2032) Table 39. Roche Company Information Table 40. Roche Business Overview Table 41. Roche RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Roche RNA-Targeted Small Molecule Drugs Product Portfolio Table 43. Roche Recent Development Table 44. Novartis Company Information Table 45. Novartis Business Overview Table 46. Novartis RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Novartis RNA-Targeted Small Molecule Drugs Product Portfolio Table 48. Novartis Recent Development Table 49. PTC Therapeutics Company Information Table 50. PTC Therapeutics Business Overview Table 51. PTC Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. PTC Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 53. PTC Therapeutics Recent Development Table 54. Biogen Company Information Table 55. Biogen Business Overview Table 56. Biogen RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Biogen RNA-Targeted Small Molecule Drugs Product Portfolio Table 58. Biogen Recent Development Table 59. Accent Therapeutics Company Information Table 60. Accent Therapeutics Business Overview Table 61. Accent Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Accent Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 63. Accent Therapeutics Recent Development Table 64. Anima Biotech Company Information Table 65. Anima Biotech Business Overview Table 66. Anima Biotech RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Anima Biotech RNA-Targeted Small Molecule Drugs Product Portfolio Table 68. Anima Biotech Recent Development Table 69. Arrakis Pharmaceuticals Company Information Table 70. Arrakis Pharmaceuticals Business Overview Table 71. Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Product Portfolio Table 73. Arrakis Pharmaceuticals Recent Development Table 74. Epics Therapeutics Company Information Table 75. Epics Therapeutics Business Overview Table 76. Epics Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Epics Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 78. Epics Therapeutics Recent Development Table 79. Expansion Therapeutics Company Information Table 80. Expansion Therapeutics Business Overview Table 81. Expansion Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Expansion Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 83. Expansion Therapeutics Recent Development Table 84. Gotham Therapeutics Company Information Table 85. Gotham Therapeutics Business Overview Table 86. Gotham Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Gotham Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 88. Gotham Therapeutics Recent Development Table 89. H3 Biomedicine Company Information Table 90. H3 Biomedicine Business Overview Table 91. H3 Biomedicine RNA-Targeted Small Molecule Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. H3 Biomedicine RNA-Targeted Small Molecule Drugs Product Portfolio Table 93. H3 Biomedicine Recent Development Table 94. Ribometrix Company Information Table 95. Ribometrix Business Overview Table 96. Ribometrix RNA-Targeted Small Molecule Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Ribometrix RNA-Targeted Small Molecule Drugs Product Portfolio Table 98. Ribometrix Recent Development Table 99. Skyhawk Therapeutics Company Information Table 100. Skyhawk Therapeutics Business Overview Table 101. Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 103. Skyhawk Therapeutics Recent Development Table 104. STORM Therapeutics Company Information Table 105. STORM Therapeutics Business Overview Table 106. STORM Therapeutics RNA-Targeted Small Molecule Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. STORM Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 108. STORM Therapeutics Recent Development Table 109. Twentyeight-Seven Therapeutics Company Information Table 110. Twentyeight-Seven Therapeutics Business Overview Table 111. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 113. Twentyeight-Seven Therapeutics Recent Development Table 114. North America RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2026) & (US$ Million) Table 115. North America RNA-Targeted Small Molecule Drugs Revenue by Type (2027-2032) & (US$ Million) Table 116. North America RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2026) & (US$ Million) Table 117. North America RNA-Targeted Small Molecule Drugs Revenue by Application (2027-2032) & (US$ Million) Table 118. North America RNA-Targeted Small Molecule Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. North America RNA-Targeted Small Molecule Drugs Revenue by Country (2021-2026) & (US$ Million) Table 120. North America RNA-Targeted Small Molecule Drugs Revenue by Country (US$ Million) & (2027-2032) Table 121. Europe RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2026) & (US$ Million) Table 122. Europe RNA-Targeted Small Molecule Drugs Revenue by Type (2027-2032) & (US$ Million) Table 123. Europe RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2026) & (US$ Million) Table 124. Europe RNA-Targeted Small Molecule Drugs Revenue by Application (2027-2032) & (US$ Million) Table 125. Europe RNA-Targeted Small Molecule Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. Europe RNA-Targeted Small Molecule Drugs Revenue by Country (2021-2026) & (US$ Million) Table 127. Europe RNA-Targeted Small Molecule Drugs Revenue by Country (US$ Million) & (2027-2032) Table 128. China RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2026) & (US$ Million) Table 129. China RNA-Targeted Small Molecule Drugs Revenue by Type (2027-2032) & (US$ Million) Table 130. China RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2026) & (US$ Million) Table 131. China RNA-Targeted Small Molecule Drugs Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2026) & (US$ Million) Table 133. Asia RNA-Targeted Small Molecule Drugs Revenue by Type (2027-2032) & (US$ Million) Table 134. Asia RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2026) & (US$ Million) Table 135. Asia RNA-Targeted Small Molecule Drugs Revenue by Application (2027-2032) & (US$ Million) Table 136. Asia RNA-Targeted Small Molecule Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 137. Asia RNA-Targeted Small Molecule Drugs Revenue by Region (US$ Million) & (2021-2026) Table 138. Asia RNA-Targeted Small Molecule Drugs Revenue by Region (US$ Million) & (2027-2032) Table 139. SAMEA RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2026) & (US$ Million) Table 140. SAMEA RNA-Targeted Small Molecule Drugs Revenue by Type (2027-2032) & (US$ Million) Table 141. SAMEA RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2026) & (US$ Million) Table 142. SAMEA RNA-Targeted Small Molecule Drugs Revenue by Application (2027-2032) & (US$ Million) Table 143. SAMEA RNA-Targeted Small Molecule Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. SAMEA RNA-Targeted Small Molecule Drugs Revenue by Country (2021-2026) & (US$ Million) Table 145. SAMEA RNA-Targeted Small Molecule Drugs Revenue by Country (US$ Million) & (2027-2032) Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. RNA-Targeted Small Molecule Drugs Image Figure 2. Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global RNA-Targeted Small Molecule Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. mRNA Translation Regulation Image Figure 5. RNA Splicing Modification Image Figure 6. Direct RNA Targeting Image Figure 7. Indirect RNA Targeting - Epitranscriptomics Image Figure 8. Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global RNA-Targeted Small Molecule Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. SMA Image Figure 11. Oncology Image Figure 12. Lung Fibrosis Image Figure 13. Huntington's Disease Image Figure 14. Others Image Figure 15. Global RNA-Targeted Small Molecule Drugs Market Size (US$ Million) & (2021-2032) Figure 16. Global RNA-Targeted Small Molecule Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global RNA-Targeted Small Molecule Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global RNA-Targeted Small Molecule Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global RNA-Targeted Small Molecule Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global RNA-Targeted Small Molecule Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Type (2021-2032) Figure 23. Global RNA-Targeted Small Molecule Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America RNA-Targeted Small Molecule Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America RNA-Targeted Small Molecule Drugs Revenue Share by Type (2021-2032) Figure 28. North America RNA-Targeted Small Molecule Drugs Revenue Share by Application (2021-2032) Figure 29. North America RNA-Targeted Small Molecule Drugs Revenue Share by Country (2021-2032) Figure 30. United States RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe RNA-Targeted Small Molecule Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe RNA-Targeted Small Molecule Drugs Revenue Share by Type (2021-2032) Figure 35. Europe RNA-Targeted Small Molecule Drugs Revenue Share by Application (2021-2032) Figure 36. Europe RNA-Targeted Small Molecule Drugs Revenue Share by Country (2021-2032) Figure 37. Germany RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China RNA-Targeted Small Molecule Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China RNA-Targeted Small Molecule Drugs Revenue Share by Type (2021-2032) Figure 47. China RNA-Targeted Small Molecule Drugs Revenue Share by Application (2021-2032) Figure 48. Asia RNA-Targeted Small Molecule Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia RNA-Targeted Small Molecule Drugs Revenue Share by Type (2021-2032) Figure 50. Asia RNA-Targeted Small Molecule Drugs Revenue Share by Application (2021-2032) Figure 51. Asia RNA-Targeted Small Molecule Drugs Revenue Share by Region (2021-2032) Figure 52. Japan RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA RNA-Targeted Small Molecule Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA RNA-Targeted Small Molecule Drugs Revenue Share by Type (2021-2032) Figure 60. SAMEA RNA-Targeted Small Molecule Drugs Revenue Share by Application (2021-2032) Figure 61. SAMEA RNA-Targeted Small Molecule Drugs Revenue Share by Country (2021-2032) Figure 62. Brazil RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt RNA-Targeted Small Molecule Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • mRNA Translation Regulation
  • RNA Splicing Modification
  • Direct RNA Targeting
  • Indirect RNA Targeting - Epitranscriptomics
Applications
  • SMA
  • Oncology
  • Lung Fibrosis
  • Huntington's Disease
  • Others
Companies covered
  • Roche
  • Novartis
  • PTC Therapeutics
  • Biogen
  • Accent Therapeutics
  • Anima Biotech
  • Arrakis Pharmaceuticals
  • Epics Therapeutics
  • Expansion Therapeutics
  • Gotham Therapeutics
  • H3 Biomedicine
  • Ribometrix
  • Skyhawk Therapeutics
  • STORM Therapeutics
  • Twentyeight-Seven Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 RNA-Targeted Small Molecule Drugs Market by Type
  3. 1.2.1 Global RNA-Targeted Small Molecule Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 mRNA Translation Regulation
  5. 1.2.3 RNA Splicing Modification
  6. 1.2.4 Direct RNA Targeting
  7. 1.2.5 Indirect RNA Targeting - Epitranscriptomics
  8. 1.3 RNA-Targeted Small Molecule Drugs Market by Application
  9. 1.3.1 Global RNA-Targeted Small Molecule Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 SMA
  11. 1.3.3 Oncology
  12. 1.3.4 Lung Fibrosis
  13. 1.3.5 Huntington's Disease
  14. 1.3.6 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 RNA-Targeted Small Molecule Drugs Market Dynamics
  1. 2.1 RNA-Targeted Small Molecule Drugs Industry Trends
  2. 2.2 RNA-Targeted Small Molecule Drugs Industry Drivers
  3. 2.3 RNA-Targeted Small Molecule Drugs Industry Opportunities and Challenges
  4. 2.4 RNA-Targeted Small Molecule Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global RNA-Targeted Small Molecule Drugs Market Perspective (2021-2032)
  2. 3.2 Global RNA-Targeted Small Molecule Drugs Growth Trends by Region
  3. 3.2.1 Global RNA-Targeted Small Molecule Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global RNA-Targeted Small Molecule Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global RNA-Targeted Small Molecule Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global RNA-Targeted Small Molecule Drugs Revenue by Players
  2. 4.1.1 Global RNA-Targeted Small Molecule Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global RNA-Targeted Small Molecule Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global RNA-Targeted Small Molecule Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global RNA-Targeted Small Molecule Drugs Key Players Headquarters & Area Served
  7. 4.4 Global RNA-Targeted Small Molecule Drugs Players, Product Type & Application
  8. 4.5 Global RNA-Targeted Small Molecule Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global RNA-Targeted Small Molecule Drugs Market CR5 and HHI
  11. 4.6.3 2025 RNA-Targeted Small Molecule Drugs Tier 1, Tier 2, and Tier 3
5 RNA-Targeted Small Molecule Drugs Market Size by Type
  1. 5.1 Global RNA-Targeted Small Molecule Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2032)
  3. 5.3 Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Type (2021-2032)
6 RNA-Targeted Small Molecule Drugs Market Size by Application
  1. 6.1 Global RNA-Targeted Small Molecule Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2032)
  3. 6.3 Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Roche
  2. 7.1.1 Roche Company Information
  3. 7.1.2 Roche Business Overview
  4. 7.1.3 Roche RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Roche RNA-Targeted Small Molecule Drugs Product Portfolio
  6. 7.1.5 Roche Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis RNA-Targeted Small Molecule Drugs Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 PTC Therapeutics
  14. 7.3.1 PTC Therapeutics Company Information
  15. 7.3.2 PTC Therapeutics Business Overview
  16. 7.3.3 PTC Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 PTC Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  18. 7.3.5 PTC Therapeutics Recent Developments
  19. 7.4 Biogen
  20. 7.4.1 Biogen Company Information
  21. 7.4.2 Biogen Business Overview
  22. 7.4.3 Biogen RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Biogen RNA-Targeted Small Molecule Drugs Product Portfolio
  24. 7.4.5 Biogen Recent Developments
  25. 7.5 Accent Therapeutics
  26. 7.5.1 Accent Therapeutics Company Information
  27. 7.5.2 Accent Therapeutics Business Overview
  28. 7.5.3 Accent Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Accent Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  30. 7.5.5 Accent Therapeutics Recent Developments
  31. 7.6 Anima Biotech
  32. 7.6.1 Anima Biotech Company Information
  33. 7.6.2 Anima Biotech Business Overview
  34. 7.6.3 Anima Biotech RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Anima Biotech RNA-Targeted Small Molecule Drugs Product Portfolio
  36. 7.6.5 Anima Biotech Recent Developments
  37. 7.7 Arrakis Pharmaceuticals
  38. 7.7.1 Arrakis Pharmaceuticals Company Information
  39. 7.7.2 Arrakis Pharmaceuticals Business Overview
  40. 7.7.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Product Portfolio
  42. 7.7.5 Arrakis Pharmaceuticals Recent Developments
  43. 7.8 Epics Therapeutics
  44. 7.8.1 Epics Therapeutics Company Information
  45. 7.8.2 Epics Therapeutics Business Overview
  46. 7.8.3 Epics Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Epics Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  48. 7.8.5 Epics Therapeutics Recent Developments
  49. 7.9 Expansion Therapeutics
  50. 7.9.1 Expansion Therapeutics Company Information
  51. 7.9.2 Expansion Therapeutics Business Overview
  52. 7.9.3 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  54. 7.9.5 Expansion Therapeutics Recent Developments
  55. 7.10 Gotham Therapeutics
  56. 7.10.1 Gotham Therapeutics Company Information
  57. 7.10.2 Gotham Therapeutics Business Overview
  58. 7.10.3 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  60. 7.10.5 Gotham Therapeutics Recent Developments
  61. 7.11 H3 Biomedicine
  62. 7.11.1 H3 Biomedicine Company Information
  63. 7.11.2 H3 Biomedicine Business Overview
  64. 7.11.3 H3 Biomedicine RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 H3 Biomedicine RNA-Targeted Small Molecule Drugs Product Portfolio
  66. 7.11.5 H3 Biomedicine Recent Developments
  67. 7.12 Ribometrix
  68. 7.12.1 Ribometrix Company Information
  69. 7.12.2 Ribometrix Business Overview
  70. 7.12.3 Ribometrix RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Ribometrix RNA-Targeted Small Molecule Drugs Product Portfolio
  72. 7.12.5 Ribometrix Recent Developments
  73. 7.13 Skyhawk Therapeutics
  74. 7.13.1 Skyhawk Therapeutics Company Information
  75. 7.13.2 Skyhawk Therapeutics Business Overview
  76. 7.13.3 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  78. 7.13.5 Skyhawk Therapeutics Recent Developments
  79. 7.14 STORM Therapeutics
  80. 7.14.1 STORM Therapeutics Company Information
  81. 7.14.2 STORM Therapeutics Business Overview
  82. 7.14.3 STORM Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 STORM Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  84. 7.14.5 STORM Therapeutics Recent Developments
  85. 7.15 Twentyeight-Seven Therapeutics
  86. 7.15.1 Twentyeight-Seven Therapeutics Company Information
  87. 7.15.2 Twentyeight-Seven Therapeutics Business Overview
  88. 7.15.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  90. 7.15.5 Twentyeight-Seven Therapeutics Recent Developments
8 North America
  1. 8.1 North America RNA-Targeted Small Molecule Drugs Revenue (2021-2032)
  2. 8.2 North America RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America RNA-Targeted Small Molecule Drugs Revenue by Type (2027-2032)
  5. 8.3 North America RNA-Targeted Small Molecule Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America RNA-Targeted Small Molecule Drugs Revenue by Application (2027-2032)
  9. 8.5 North America RNA-Targeted Small Molecule Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America RNA-Targeted Small Molecule Drugs Revenue by Country
  11. 8.6.1 North America RNA-Targeted Small Molecule Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America RNA-Targeted Small Molecule Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America RNA-Targeted Small Molecule Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe RNA-Targeted Small Molecule Drugs Revenue (2021-2032)
  2. 9.2 Europe RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe RNA-Targeted Small Molecule Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe RNA-Targeted Small Molecule Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe RNA-Targeted Small Molecule Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe RNA-Targeted Small Molecule Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe RNA-Targeted Small Molecule Drugs Revenue by Country
  11. 9.6.1 Europe RNA-Targeted Small Molecule Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe RNA-Targeted Small Molecule Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe RNA-Targeted Small Molecule Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China RNA-Targeted Small Molecule Drugs Revenue (2021-2032)
  2. 10.2 China RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China RNA-Targeted Small Molecule Drugs Revenue by Type (2027-2032)
  5. 10.3 China RNA-Targeted Small Molecule Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China RNA-Targeted Small Molecule Drugs Revenue by Application (2027-2032)
  9. 10.5 China RNA-Targeted Small Molecule Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia RNA-Targeted Small Molecule Drugs Revenue (2021-2032)
  2. 11.2 Asia RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia RNA-Targeted Small Molecule Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia RNA-Targeted Small Molecule Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia RNA-Targeted Small Molecule Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia RNA-Targeted Small Molecule Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia RNA-Targeted Small Molecule Drugs Revenue by Country
  11. 11.6.1 Asia RNA-Targeted Small Molecule Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia RNA-Targeted Small Molecule Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia RNA-Targeted Small Molecule Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA RNA-Targeted Small Molecule Drugs Revenue (2021-2032)
  2. 12.2 SAMEA RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA RNA-Targeted Small Molecule Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA RNA-Targeted Small Molecule Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA RNA-Targeted Small Molecule Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA RNA-Targeted Small Molecule Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA RNA-Targeted Small Molecule Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA RNA-Targeted Small Molecule Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA RNA-Targeted Small Molecule Drugs Revenue by Country
  11. 12.6.1 SAMEA RNA-Targeted Small Molecule Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA RNA-Targeted Small Molecule Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA RNA-Targeted Small Molecule Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst